Introduction
============

The tobacco plant is native to South America, Mexico, and the West Indies.[@b1-cpaa-2-017] The American Indians used various forms of tobacco for its medicinal properties for hundreds of years before the discovery of the New World by Christopher Columbus. [@b1-cpaa-2-017] The common tobacco, *Nicotiana tabacum*, is named after Jean Nicot, the French ambassador to Lisbon, who is believed to have sent its seeds to Catherine de Medicis, the queen consort and regent of France in 1566.[@b1-cpaa-2-017] Nicotine was first extracted in its crude form in 1571, purified form in 1928, and synthesized in a laboratory in 1904.[@b1-cpaa-2-017] Over the decades, the causative role of smoking, and other forms of tobacco use, in cancer has been well-established. This article reviews the pharmacological agents currently used for smoking cessation. These include the various forms of nicotine replacement products, varenicline, bupropion sustained release, nortriptyline, and clonidine. A brief overview of the epidemiology of smoking, the chemistry and pharmacology of nicotine, and adverse health consequences of smoking is provided as a background to better understand the use of pharmacological agents for smoking cessation.

Epidemiology
============

Cigarette smoking is the most popular method of using tobacco; other forms of smoking and tobacco use are summarized in [Table 1](#t1-cpaa-2-017){ref-type="table"}.[@b2-cpaa-2-017]--[@b4-cpaa-2-017] Worldwide, tobacco use causes more than 5 million deaths per year and if the current trends in the use of tobacco continue, it will cause 8 million deaths per year by 2030.[@b5-cpaa-2-017] Cigarette smoking is the leading preventable cause of death in the United States, responsible for about one in five or half-million deaths every year.[@b4-cpaa-2-017] Exposure to environmental tobacco smoke (ETS) results in an estimated 49,000 deaths every year.[@b2-cpaa-2-017] Smoking and use of other forms of tobacco by youth is of particular significance, with 60% of new smokers being under the age of 18 when they first smoked a cigarette.

In 2007, more than 3 million American adolescents (aged 12--17) reported using a tobacco product in the month prior to the survey.[@b2-cpaa-2-017] Tobacco use by adolescents is influenced by multiple psychosocial and biological factors that increase adolescents' vulnerability for nicotine use.[@b2-cpaa-2-017],[@b6-cpaa-2-017],[@b7-cpaa-2-017] Studies show that adolescents are more sensitive to the reinforcing effects of nicotine and other chemicals found in cigarettes, further increasing their susceptibility to tobacco addiction. Intermittent smoking, such as over the weekends or at parties, has also been shown to result in tobacco addiction in adolescents. Tobacco use, especially the smokeless forms, is of special concern in athletes.[@b8-cpaa-2-017]--[@b15-cpaa-2-017]

Electronic cigarettes are a new trend and a major concern for young smokers.[@b16-cpaa-2-017],[@b17-cpaa-2-017] Electronic cigarettes are marketed to young smokers and are easily available over the internet and in shopping malls. The labeling on these cigarettes does not include the United States Food and Drug Administration (US FDA) warning of its harmful effects.[@b16-cpaa-2-017] Also called e-cigarettes, these are battery-operated devices that generally contain cartridges filled with nicotine, flavor and other chemicals. The electronic cigarette turns nicotine and other chemicals into vapor that is inhaled by the user. The US FDA has found that this form of cigarette is equally harmful, toxic, and addictive as other forms of tobacco use.[@b16-cpaa-2-017],[@b17-cpaa-2-017] In addition to various carcinogens, e- cigarettes also contain other chemicals such as diethylene glycol, which is an ingredient found in antifreeze liquid.[@b16-cpaa-2-017]

Chemistry and pharmacology
==========================

Approximately 4,000 chemicals are found in the smoke of tobacco products, of which nicotine is primarily responsible for tobacco addiction.[@b2-cpaa-2-017],[@b6-cpaa-2-017],[@b7-cpaa-2-017] The chemistry and neuropharmacology of nicotine has been extensively studied.[@b18-cpaa-2-017]--[@b21-cpaa-2-017] Other main constituents of smoke that result in adverse health consequences include ammonia, benzene, carbon monoxide, cyanide, formaldehyde, acetaldehyde, phenols, and tar. Approximately 90% of the constituents of the smoke are in the form of vaporized chemicals, while rest are in the particulate form.[@b2-cpaa-2-017],[@b4-cpaa-2-017],[@b22-cpaa-2-017]

Cigarettes are categorized ([Table 1](#t1-cpaa-2-017){ref-type="table"}) based on their tar content (total particulate matter in smoke, excluding water and alkaloid compounds), which is measured using a standardized protocol on a smoking machine.[@b2-cpaa-2-017]--[@b4-cpaa-2-017] In filtered cigarettes (99% of cigarettes currently on the market), the filter vents dilute the smoke with air, reducing standard yields of tar, nicotine, and carbon monoxide. Many smokers block the vents or compensate with increased inhalations when smoking low-yield cigarettes. By doing so, they typically get as much tar and nicotine from cigarettes with low-yield ratings as those with higher yields. On average a cigarette contains between 13--19 mg of nicotine; smoking 1 cigarette typically delivers 1--2 mg of nicotine.[@b2-cpaa-2-017],[@b6-cpaa-2-017],[@b7-cpaa-2-017] The nicotine content of tobacco smoke is 1%--2% and each inhalation delivers approximately 0.05--0.15 mg.[@b2-cpaa-2-017],[@b7-cpaa-2-017]

Smoke is produced by the incomplete combustion of tobacco. The fate of the cigarette smoke is depicted in [Figure 1](#f1-cpaa-2-017){ref-type="fig"}.[@b22-cpaa-2-017] Mainstream smoke--the smoke inhaled by the smoker directly through the mouthpiece of the cigarette--constitutes approximately 45% of the total smoke; whereas side stream smoke, which is the smoke emitted by smoldering tobacco between puffs and the smoke diffusing through the lit cigarette paper and escaping from the burning cone during smoking, constitutes 55% of the total smoke.[@b22-cpaa-2-017]

Nicotine, whose chemical structure resembles that of the neurotransmitter acetylcholine, acts on stereospecific nicotinic cholinergic receptors (nAChRs) in the brain and other organs.[@b7-cpaa-2-017],[@b21-cpaa-2-017] The chemical structure and metabolic pathway of nicotine is depicted in [Figure 2](#f2-cpaa-2-017){ref-type="fig"}. It also has both direct and indirect effects on the neuroendocrine system. The initial phase of stimulation of the central nervous system (CNS) by nicotine is typically followed by a phase of CNS depression.[@b7-cpaa-2-017],[@b20-cpaa-2-017] The action of nicotine on nAChRs stimulates the release of various neurotransmitters and hormones including acetylcholine, norepinephrine, dopamine, vasopressin, serotonin, and beta-endorphins.[@b2-cpaa-2-017],[@b6-cpaa-2-017],[@b7-cpaa-2-017],[@b19-cpaa-2-017] Research shows that smoking is associated with a marked decrease in monoamine oxidase (MAO) levels in the brain.[@b7-cpaa-2-017] It is postulated that this decrease in MAO is caused by chemicals in the smoke other than nicotine. Decreased levels of MAO-A and MAO-B in the brain result in a higher level of dopamine. The action of nicotine on the CNS increases alertness, improves memory, improves concentration, and decreases anxiety. The pharmacokinetic properties of nicotine are summarized in [Table 2](#t2-cpaa-2-017){ref-type="table"}.[@b2-cpaa-2-017],[@b4-cpaa-2-017],[@b7-cpaa-2-017],[@b8-cpaa-2-017],[@b21-cpaa-2-017]

Effects on health
=================

The wide-ranging adverse effects of tobacco use have been well-established and well-documented.[@b2-cpaa-2-017],[@b4-cpaa-2-017],[@b6-cpaa-2-017],[@b22-cpaa-2-017]--[@b28-cpaa-2-017] The numerous harmful health consequences of smoking are summarized in [Table 3](#t3-cpaa-2-017){ref-type="table"}.

Nicotine activates reward pathways in the brain that regulate feelings of pleasure.[@b7-cpaa-2-017] These effects of nicotine are mediated by dopamine. Nicotine increases levels of dopamine mainly by its action on the mesolimbic dopamine system.[@b7-cpaa-2-017],[@b21-cpaa-2-017] Chronic use of nicotine results in an increase in the number of nicotine receptors in the brain.[@b6-cpaa-2-017],[@b7-cpaa-2-017],[@b19-cpaa-2-017] Consequently, more nicotine is required to achieve the desired effect, eventually resulting in tolerance and dependence. Regular tobacco use results in nicotine accumulation in the body, exposing the user to the effects of nicotine throughout the 24 hours. Nicotine levels in the brain and the associated feelings of pleasure and reward peak within 10 seconds of inhalation.[@b2-cpaa-2-017],[@b4-cpaa-2-017],[@b7-cpaa-2-017] However, the acute effects of nicotine dissipate rapidly. This causes the smoker to continue to smoke to maintain the effects of the nicotine and prevent withdrawal symptoms. The significant neurochemical changes in the brain that result from chronic nicotine use make it very difficult for the smoker to quit. Animal studies have shown that acetaldehyde, a chemical found in tobacco smoke, dramatically increases the reinforcing properties of nicotine and may also contribute to tobacco addiction.[@b2-cpaa-2-017],[@b4-cpaa-2-017],[@b7-cpaa-2-017] Adolescent animals show far more sensitivity to this reinforcing effect, suggesting increased vulnerability of adolescents to tobacco addiction.

Abrupt cessation of smoking results in withdrawal symptoms primarily due to decreased nicotine levels. Symptoms of nicotine withdrawal include: irritability; craving; depression; anxiety; cognitive and attention deficits; sleep disturbances; and increased appetite.[@b6-cpaa-2-017],[@b22-cpaa-2-017] The withdrawal symptoms, in most cases, begin within a few hours after the last cigarette, peak within the first few days of smoking cessation, and usually subside within a few weeks. In some cases, however the symptoms may persist for months.[@b4-cpaa-2-017],[@b6-cpaa-2-017]

The role of behavioral approaches to smoking cessation
======================================================

Behavioral treatment is integral to smoking cessation -- studies have shown that a combination of behavioral and pharmacological treatment is more effective than either approach alone.[@b3-cpaa-2-017],[@b29-cpaa-2-017]--[@b32-cpaa-2-017] Fiore and colleagues provide an extensive analysis of scientific evidence supporting the optimal efficacy of the combined behavioral and pharmacological approach for smoking cessation. The results of their meta-analysis of published studies indicate that providing counseling in addition to medication significantly enhanced treatment outcome -- for medication alone the odds ratio (95% confidence interval \[CI\]) was 1.0, and estimated abstinence rate (95% CI) was 21.7, whereas for medication and counseling the estimated odds ratio (95% CI) was 1.4 (1.2--1.6), and estimated abstinence rate (95% CI) was 27.6 (25.0--30.3).[@b3-cpaa-2-017] Conversely, Fiore and colleagues also found that providing medication in addition to counseling also significantly enhanced treatment outcome -- for counseling alone the estimated odds ratio (95% CI) was 1, and estimated abstinence rate (95% CI) was 14.6, whereas for medication and counseling the estimated odds ratio (95% CI) was 1.7 (1.3--2.1) and the estimated abstinence rate (955 CI) was 22.1 (18.1--26.8).[@b3-cpaa-2-017]

In addition to the neurochemical effects of nicotine, behavioral factors also affect the severity of nictotine withdrawal symptoms. For some people, the feel, smell, and sight of a cigarette and the ritual of obtaining, handling, lighting, and smoking a cigarette are all associated with the pleasurable effects of smoking. Consequently, this can worsen withdrawal symptoms or cravings. Behavioral therapies can help smokers identify environmental triggers of craving so they can employ strategies to prevent or circumvent these symptoms and urges. It is important to recognize that smoking cessation is a team effort. The social setting in which smoking occurs, the social culture of the smoker, and the support networks available to the smoker, all play critical role in the success of smoking cessation by the smoker. Among the professionals, the pharmacist plays a critical role in providing ongoing support, education, and counseling.

Pharmacological agents
======================

General factors, which should to be considered when prescribing pharmacological agents for smoking cessation, are summarized in [Table 4](#t4-cpaa-2-017){ref-type="table"}. Patients who smoke may be on therapeutic drugs for other chronic diseases. The effective dosages of these therapeutic drugs reflect the adjustments made because of concomitant exposure to nicotine. With smoking cessation and elimination of nicotine from the body, a new state of metabolic homeostasis will result that may necessitate adjusting dosage of therapeutic drugs. Drug-drug interactions are an important consideration when using pharmacotherapy for smoking cessation, especially in smokers who are on other medications for chronic diseases. Smoking induces some isoforms of the hepatic cytochrome P450.[@b3-cpaa-2-017] Nicotine, although metabolized by CYPP2A6, is not a significant inducer of CYP enzymes.[@b3-cpaa-2-017] Therefore, when smoker quits with or without being on nicotine replacement therapy, the baseline functioning of the P450 enzyme system is restored, and can increase the serum levels of certain drugs (eg, fluvoxamine, olanzepine, clozapine), resulting in their increased side-effects.[@b3-cpaa-2-017] Nicotine replacement therapy may reduce the sedative effects of benzodiazepines, subcutaneous absorption of insulin, and the blood pressure lowering effect of some beta-blockers.[@b3-cpaa-2-017] Some drugs reported to have significant interactions with bupropion include: cyclophosphamide; orphenadrine; tricyclic antidepressants; antipsychotics; certain antiarrhythmic drugs; certain beta-blockers; carbamazepine; phenytoin; phenobarbital; valproate; and cimetidine.[@b3-cpaa-2-017] Varenicline is not reported to have specific significant drug-drug interactions.

Tobacco dependence should be considered a chronic disease and as such its management requires on-going patient education, counseling, and use of medications as indicated.[@b3-cpaa-2-017] Relapses are common during smoking cessation and patients require long-term monitoring and treatment. Long-term pharmacotherapy, combination therapy, and re-use of drugs previously used (recycling) should be considered in relapse prevention and treatment. In some patients who are not able to quit completely, pharmacotherapy has been used to reduce smoking, with some achieving a 50% reduction in smoking.[@b3-cpaa-2-017],[@b7-cpaa-2-017] With pharmacotherapy, the estimated 6-month abstinence rate is about 20%, compared to approximately 10% without pharmacotherapy. [@b3-cpaa-2-017],[@b6-cpaa-2-017],[@b7-cpaa-2-017] All pharmacologic agents have been shown to be effective in smoking cessation with odds ratios between two and four when compared to placebo treatment. [@b3-cpaa-2-017],[@b6-cpaa-2-017] Absolute smoking cessation rates vary depending on the particular pharmacologic agent used and the intensity of concomitant counseling; rates vary in range from 5% to 35%.[@b3-cpaa-2-017],[@b6-cpaa-2-017],[@b7-cpaa-2-017] The smoker's likelihood of long-term abstinence doubles with the use of nicotine inhaler, nicotine lozenge, nicotine nasal spray, or nicotine patch.[@b3-cpaa-2-017] Smith and colleagues looked at comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. They reported 6 month abstinence rates for the 5 active pharmacotherapies as follows: bupropion SR, 16.8%; lozenge, 19.9%; patch, 17.7%; patch + lozenge, 26.9%; and bupropion SR + lozenge, 29.9%.[@b29-cpaa-2-017] In a recent study Garrison and Dugan reported a quit rate for varenicline that ranged from approximately 40% to 65%.[@b31-cpaa-2-017]

The first-line drugs for smoking cessation approved by the US Food and Drug Administration (FDA) are varenicline, bupropion sustained release (SR), and nicotine replacement drugs.[@b3-cpaa-2-017],[@b33-cpaa-2-017]--[@b44-cpaa-2-017] These drugs are approved by the FDA for use in adults. Data are insufficient to assess their efficacy in adolescents.[@b3-cpaa-2-017] Pharmacotherapy has not been shown to be effective in light smokers and in those who use smokeless tobacco.

Varenicline
-----------

Varenicline acts by selective binding at α4β2 neuronal nicotinic acetylcholine receptors, which results in agonist activity, while simultaneously preventing nicotine binding to α4β2 receptors.[@b7-cpaa-2-017],[@b39-cpaa-2-017]--[@b41-cpaa-2-017] The FDA recommendation for varenicline product label includes a warning that serious neuropsychiatric symptoms have been reported in patients being treated with this drug. Varenicline, therefore, should preferably be avoided in persons who have a history of neuropsychiatric disorders. It is not uncommon for patients to experience feelings of depression, anxiety, irritability, and sleep disturbances during smoking cessation. Although some of these symptoms may be associated with nicotine withdrawal, symptoms have occurred in patients who continued to smoke. Patients on varenicline should be monitored for agitation, depressed mood, and changes in behavior that are not typical for the patient. The patient also must be assessed for suicidal ideation or suicidal behavior. Varenicline is reported to be well-tolerated for up to 1 year and may reduce the incidence of relapse.[@b41-cpaa-2-017] Prescribing information for varenicline is summarized in [Table 5](#t5-cpaa-2-017){ref-type="table"}.

Bupropion sustained release (SR)
--------------------------------

The proposed mechanisms of action of bupropion sustained release (SR) include the blockade of neuronal re-uptake of dopamine and norepinephrine.[@b42-cpaa-2-017] Similar to varenicline, bupropion SR also carries an FDA warning for neuropsychiatric adverse events. Bupropion lowers the seizure threshold and is contraindicated in persons with a history of seizure disorder and those who are on other medications that lower the seizure threshold.[@b3-cpaa-2-017] It is also contraindicated in persons who have a prior or current history of eating disorder because of an increased risk for seizures.[@b3-cpaa-2-017] Bupropion SR is also an anti-depressant and like other anti-depressant drugs, it carries a warning for increased risk of suicidal ideation. Patients on bupropion should therefore be closely monitored for emerging neuropsychiatric symptoms and signs of suicidal ideation. Prescribing information for bupropion SR for smoking cessation is summarized in [Table 6](#t6-cpaa-2-017){ref-type="table"}.

Nicotine replacement therapies
------------------------------

Nicotine replacement therapy (NRT) drugs reduce craving and withdrawal symptoms by partially replacing lost nicotine intake. The main characteristics and prescribing information of available NRT products are summarized in [Tables 7](#t7-cpaa-2-017){ref-type="table"} through [Table 11](#t11-cpaa-2-017){ref-type="table"}.[@b3-cpaa-2-017],[@b29-cpaa-2-017],[@b33-cpaa-2-017]--[@b35-cpaa-2-017],[@b43-cpaa-2-017],[@b44-cpaa-2-017]

Second-line medications
-----------------------

Clonidine and nortriptyline are second-line medications used for smoking cessation.[@b3-cpaa-2-017],[@b45-cpaa-2-017] Although second-line medications have been shown to be effective in treating tobacco dependence, their use is limited mainly because of less favorable side-effect profile when compared to the first-line medications. Second-line medications are not approved by the FDA specifically for use in smoking cessation. [@b3-cpaa-2-017] Second-line medications should be considered for use on a case-by-case basis after first-line medications (either alone or in combination) have been used without success, or are contraindicated.[@b3-cpaa-2-017]

Clonidine is contraindicated in pregnant women and in those who engage in potentially hazardous activities. The most common side effects of clonidine include dry mouth (40%), drowsiness (33%), dizziness (16%), sedation (10%) and constipation (10%).[@b3-cpaa-2-017] Because abrupt discontinuation of clonidine can result in severe rebound hypertension, it should be tapered. Clonidine is available as 0.1 mg, 0.2 mg, and 0.3 mg scored tablets and 0.1 mg/24 hours, 0.2 mg/24 hours, and 0.3 mg/24 hours transdermal patches. The usual dosage is 0.2 mg--0.6 mg per day in divided doses.[@b3-cpaa-2-017],[@b45-cpaa-2-017] Specific dosage of clonidine for smoking cessation has not been established.

Nortriptyline is a tricyclic antidepressant and therefore carries an FDA warning about increased suicide risk.[@b3-cpaa-2-017] The most serious side effects of nortriptyline are arrhythmias and impairment of myocardial contractility. More common and less serious side effects include sedation, dry mouth, blurred vision, urinary retention, lightheadedness, and shaky hands.[@b3-cpaa-2-017] Nortriptyline is available as 10 mg, 25 mg, 50 mg, and 75 mg capsules and 10 mg/5 mL liquid. The dosage of nortriptyline in smoking cessation studies ranges between 25 mg per day and 100 mg per day.[@b3-cpaa-2-017],[@b45-cpaa-2-017],[@b46-cpaa-2-017] Therapeutic drug level and cardiovascular monitoring, including electrocardiogram (ECG), is recommended.

Several investigators have reported on the use of iontophoresis and chemical enhancers to deliver nortriptyline and other smoking cessation agents transdermally. Escobar-Chavez and colleagues report that the controlled delivery of a chemical through the skin can be achieved by constant current iontophoresis.[@b47-cpaa-2-017] This involves the application of a small electrical potential and is unique to iontophoresis. The amount of compound delivered by iontophoresis is directly proportional to the quantity of charge passed, the current applied, the duration of current application, and the area of the skin surface in contact with the active electrode compartment.[@b47-cpaa-2-017] Melero and colleagues reported on results of their study on delivery of nortriptyline using iontophoresis.[@b48-cpaa-2-017] They noted that the highest flux obtained would provide the recommended doses for smoking cessation support therapy (25--75 mg) with a 2 cm × 2 cm patch or 3.5 cm × 3.5 cm patch, respectively, without skin damage.[@b48-cpaa-2-017] Merino and colleagues reported on the use of chemical enhancers and ionotphoresis to enhance transdermal delivery of nortriptyline. [@b49-cpaa-2-017] They also noted that iontophoresis could be used to provide therapeutic concentrations of the drug in smoking cessation treatment.

Conclusion
==========

Tobacco use remains a great public health concern, especially in adolescents. The significant health hazards of smoking and other forms of tobacco use are well-documented. Smoking can also adversely affect exercise and sports performance. Tobacco addiction is primarily caused by nicotine, though other chemicals contained within tobacco products are now believed to play a secondary role in addiction. A combined behavioral and pharmacological approach has been found to be more effective for smoking cessation than either approach used alone. The importance of team effort in any smoking cessation strategy should be recognized. The environmental factors and public policies play important roles in population wide smoking cessation efforts. Considerable evidence supports the role of the pharmacist in the management of chronic diseases, including smoking cessation. To decrease the overall burden of smoking, all healthcare practitioners need to work together. A range of pharmacological agents and behavioral therapies are available for smoking cessation.

Varenicline, bupropion SR, and nicotine replacement therapies are recommended as first-line drugs for smoking cessation. In selected cases the first-line drugs may also be used in combination with each other to improve outcomes. Treatment interventions have been shown to double the rate of smoking cessation when compared to quit attempts without intervention. Tobacco dependence should be considered a chronic disease with anticipated relapses requiring long-term monitoring and treatment.

Authors thank Kim Douglas for assistance with the preparation of this manuscript. Data in [Table 5](#t5-cpaa-2-017){ref-type="table"} to [Table 11](#t11-cpaa-2-017){ref-type="table"} are derived from: 1) Fiore MC, Jaen CR, Baker TB, et al Treating Tobacco Use and Dependence 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. May 2008; 2) Food and Drug Administration product information available at [www.fda.gov](www.fda.gov); 3) Drug manufacturer product labels available at manufacturer web sites; including following web sites:

Chantix <http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021928s007lbl.pdf>; Zyban <http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm176815.htm>; Nicotrol inhaler <http://media.pfizer.com/files/products/uspi_nicotrol_inhaler.pdf>; Nicotrol NS <http://media.pfizer.com/files/products/uspi_nicotrol.pdf>; Nicoderm CQ <http://www.nicodermcq.com/>; Commit <http://www.commitlozenge.com/>; Nicorette <http://www.nicorette.com/>
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###### 

Main forms of tobacco used

  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cigarettes                        Cigarette brands are categorized based on their tar content:\
                                    Ultra-light 1--6 mg tar\
                                    Light 6--15 mg tar\
                                    Full-flavor \>15 mg tar\
                                    Of all cigarettes sold in the United States, 84% are either light or ultra-light. Low-yield cigarettes and cigarette-like products are examples of a classification of products referred to as "potentially reduced-exposure products" (PREPs).

  Cigars                            Cigars contain the same toxic and carcinogenic compounds found in cigarettes. The three major types of cigars sold in the United States are large cigars, cigarillos, and little cigars.

  Bidis                             Bidis are small, thin hand-rolled cigarettes imported to the United States primarily from India and other Southeast Asian countries. They consist of tobacco wrapped in a tendu or temburni leaf (plants native to Asia), and may be secured with a colorful string at one or both ends. They have higher concentrations of nicotine, tar, and carbon monoxide than conventional cigarettes sold in the United States.

  Kreteks                           Kreteks (clove cigarettes) imported from Indonesia, typically contain a mixture consisting of tobacco, cloves, and other additives. Kreteks deliver more nicotine, carbon monoxide, and tar than conventional cigarettes.

  Smokeless tobacco                 Chewing tobacco comes in the form of loose leaf, plug, or twist. Snuff is finely ground tobacco that can be dry, moist, or in sachets (tea bag-like pouches). Although some forms of snuff can be used by sniffing or inhaling into the nose, most smokeless tobacco users place the product in their cheek or between their gum and cheek. Users then suck on the tobacco and spit out the tobacco juices, which is why smokeless tobacco is often referred to as spit or spitting tobacco.

  Betel quid with tobacco (Gutka)   Gutka (ghutka or gutkha) is a dry, relatively nonperishable commercial preparation that consists of betel leaf (*Piper betle*), tobacco, areca nut (*Areca catechu*), catechu (extract of the *Acacia catechu* tree), and slaked lime (calcium hydroxide). Gutka is available in sachets and tins. It is consumed by placing a pinch of the mixture in the mouth between the gum and cheek and gently sucking and chewing. The excess saliva produced by chewing may be swallowed or spit out. Gutka is primarily consumed in the Indian subcontinent (India, Pakistan, and Bangladesh).\
                                    In the Indian subcontinent, nonperishable, commercially manufactured preparations of betel quid without tobacco are known as pan masala, and freshly prepared betel quid (with or without tobacco) is known as pan.
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Based on data from: Centers for Disease Control and Prevention. Smoking and tobacco use: fact sheets. Available at <http://www.cdc.gov/tobacco/data_statistics/fact_sheets>. Accessed August 11, 2009.

###### 

Pharmacokinetics of nicotine[@b2-cpaa-2-017],[@b4-cpaa-2-017],[@b7-cpaa-2-017],[@b8-cpaa-2-017],[@b21-cpaa-2-017]

  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Absorption     10%--50% of available nicotine is absorbed during puffing; 80% during deep inhalationReadily and completely absorbed via mucous membranes and skin
  Distribution   Readily distributed in all body tissuesReaches brain within 10 sAcute spike in arterial nicotine level occursSteady state volume of distribution is approximately 2.6 times the body weight in kg
  Metabolism     80% is metabolized in the liver to continine by enzyme CYP2A6 (and to a lesser extent by CYP2B6 and CYP2E1)Rest is metabolized in the lungs and kidneys
  Elimination    Average elimination half-life is 2 hAverage elimination half-life of nicotine metabolite cotinine is 16 hCotinine is not detectable in urine after complete abstinence of 1 wkUnaltered nicotine and its metabolites excreted by kidneys
  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Adverse health effects of smoking and tobacco use

  Disease                                                         
  --------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cancer**                                                      Bladder cancerCervical cancerEsophageal cancerKidney cancerLaryngeal cancerLeukemiaLung cancerOral cancerPancreatic cancerStomach cancer
  **Cardiovascular diseases**                                     Abdominal aortic aneurysmAcute and episodic increase in blood pressureAcute increase in peripheral vascular resistance and blood pressureAtherosclerosisCerebrovascular diseaseCoronary heart diseaseDecreased coronary blood flow (due to constriction of coronary arteries)Decreased oxygen carrying capacity of the hemoglobinHypertensionIncreased baseline heart rateIncreased oxygen demands of the myocardium (due to increased heart rate and blood pressure)Increased risk for thromboembolismIncreased risk of ventricular arrhythmias and sudden death (due to increased platelet adhesiveness, releasing catecholamines causing acute thrombosis and promoting ventricular arrhythmias)Peripheral vascular disease
  **Respiratory diseases**                                        BronchiolitisBronchitisChronic coughChronic obstructive pulmonary diseaseDecreased forced expiratory volume (FEV~1~)Decreased peak expiratory flow rate (PEFR)Development and exacerbation of asthmaDyspneaEosinophilic granulomaHalitosisHoarsenessIdiopathic pulmonary fibrosisImpaired lung growthImpaired respiratory immunityIncreased respiratory allergiesInterstitial lung diseaseLaryngitisOtitis media and middle ear effusionsPneumoniaPulmonary hemorrhagePulmonary hypertensionRhinitisSinusitisSnoringSpontaneous pneumothoraxUpper respiratory infections
  **Reproductive effects**                                        FertilityFetal death and stillbirthsLow birth weightPregnancy complicationsPremature menopause
  **Musculoskeletal**                                             Decreased bone mineral densityIncreased risk for fracturesIncreased spinal disk disease
  **Gastrointestinal**                                            Decreased appetiteGastroesophageal reflux diseaseImpaired glucose toleranceIncrease insulin resistancePeptic ulcer disease
  **Mental health and psychosocial**                              AddictionAnxiety, palpitations, tremorsNervousness, depressionTolerance and dependenceWithdrawal symptoms
  **Effects on offspring of maternal smoking during pregnancy**   Certain childhood cancersIncreased cotinine in breastfed infants if mother smokesIncreased incidence of conduct disordersIncreased probability of female children to be smokersLow birth weightMiscarriagePrematuritySudden infant death syndrome
  **Specific effects of smokeless tobacco use**                   Excess salivationGingivitis, gingival recessionHalitosisLeukoplakiaOropharyngeal cancersPeriodontal diseaseStaining of teeth
  **Other effects**                                               Altered lipid profileAltered metabolism of therapeutic drugsAnorexia and weight lossCataractsDecreased exercise performanceDiminished health status/increased morbidityEsophagitisGastroesophageal reflux diseaseHip fracturesLow bone densityMacular degenerationNicotine addiction (tolerance dependence, withdrawal symptoms)OsteoporosisPeptic ulcer diseaseSpinal disk disease

**Sources:** U.S. Department of Health Education, and Welfare 1964, 1967, 1979; U.S. Department of Health and Human Services 1980, 1982, 1983, 1984, 1989, 1990, 1994, 2001. Data from: (1) U.S. Department of Health and Human Services: The Health Consequences of Smoking. Nicotine Addiction: A Report of the Surgeon General. Washington, DC, 1988 U.S. Department of Health and Human Services; (2) The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health, 2004. Available at <http://www.cdc>,gov/tobacco/data_statistics/sgr_2004/index.htm. Accessed August 11, 2009.

###### 

Factors to be considered in the use of smoking cessation drugs

  ---------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Practical considerations                       Health insurance coverage, out-of-pocket costs, likelihood of adherence, dentures when considering the gums, or dermatitis when considering the patch.
  Patient's prior experience with a medication   Prior successful experience (sustained abstinence with the medication) suggests that the medication may be helpful to the patient in a subsequent quit attempt, especially if the patient found the medication to be tolerable and or easy to use. However, it is difficult to draw firm conclusions from prior failure with a medication.
  Environmental factors                          Consider the importance of smoker's social setting, social culture, and support networks. These and other environmental factors play important role in the success of any smoking cessation strategy.
  Heavy users or smokers                         The higher-dose preparations of nicotine gum, patch, and lozenge have been shown to be effective in highly dependent smokers. Combination nicotine replacement therapy (NRT) may be particularly effective in suppressing tobacco withdrawal symptoms. NRT combinations are especially helpful for highly dependent smokers or those with a history of severe withdrawal.
  Light users or smokers                         Cessation medications generally not beneficial to light smokers. If NRT is used with light smokers, consider reducing the dose of the medication. No adjustments are necessary when using bupropion SR or varenicline.
  Gender                                         NRT can be effective with both sexes; however, evidence is mixed as to whether NRT is less effective in women than men. This may encourage the clinician to consider use of another type of medication with women, such as bupropion SR or varenicline.
  Weight gain concern                            Bupropion SR and nicotine replacement therapies, in particular 4-mg nicotine gum and 4-mg nicotine lozenge, delay -- but do not prevent -- weight gain.
  Depression                                     Bupropion SR and nortriptyline appear to be effective, but nicotine replacement medications also appear to help individuals with a history of depression.
  History of cardiovascular disease              The nicotine patch has been demonstrated safe for patients with a history of cardiovascular disease.
  Long-term use                                  Long-term use is helpful with smokers who report persistent withdrawal symptoms during the course of medications, who have relapsed in the past after stopping medication, or who desire long-term therapy. A minority of individuals who successfully quit smoking use *ad libitum* NRT medications (gum, nasal spray, inhaler) long-term. The use of these medications for up to 6 months does not present a known health risk and developing dependence on medications is uncommon. The FDA has approved the use of bupropion SR, varenicline, and some NRT medications for 6-month use.
  Combination therapy                            Combining the nicotine patch long-term (\>14 weeks) with nicotine gum or nicotine nasal spray, the nicotine patch with the nicotine inhaler, or the nicotine patch with bupropion SR, increases long-term abstinence rates relative to placebo treatments. Combining varenicline with NRT agents has been associated with higher rates of side effects (eg, nausea, headaches).
  ---------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Sources:** Copyright © 2008. Modified with permission from: Fiore MC, Jaen CR, Baker TB, et al. *Treating Tobacco Use and Dependence 2008 Update. Clinical Practice Guideline*. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 2008.

###### 

Varenicline^Rx^

  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product         Chantix^®^ (Pfizer, Inc., New York City, NY) 0.5 mg, 1 mg tablet

  Precautions     PregnancyMay worsen pre-existing psychiatric illnessDosage adjustment required in patients with kidney disease (creatinine clearance less than 30 ml/min) or who are on dialysisWARNING: Can cause depressed mood, agitation, change in behavior, suicidal ideation, suicide. Reported in patients attempting to quit smoking while using varenicline. Monitor closely.

  Dosage          Recommended: 1-week titration:\
                  Days 1--3: 0.5 mg tablet daily\
                  Days 4--7: 0.5 mg tablet BID (AM and HS)\
                  Days 8+: 1 mg tablet BID (AM and HS) Set quit dateStart one week before quit dateTake after eating and with a full glass of waterNausea is dose related; if persistent and troubling, consider dose reduction. Duration: 12 wk; if successful after 12 week, an additional 12 week is recommended for increased likelihood of long-term abstinence

  Side effects    Dose dependent nausea (most common)InsomniaAbnormal dreamsHeadacheDyspepsiaConstipationFlatulenceVomiting

  Advantages      Provides nicotine effects to reduce withdrawal symptoms and cravingsBlocks the nicotine effects from smoking and reduces reward of smokingMay be used in those with cardiovascular diseaseNo clinically meaningful drug interactionsFound to be more effective than bupropion SR

  Disadvantages   Not studied in combination with other therapiesNausea associated with higher doses may be bothersomeDoes not reduce weight gainMay cause impaired ability to drive or operate heavy machineryMay cause neuropsychiatric symptoms including behavioral changes, agitation, depressed mood, suicidal ideation, and suicidal behavior
  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Bupropion SR^Rx^

  ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product             Zyban^®^ (GlaxoSmithKline plc, Brentford, London, England, UK), Generic 150 mg sustained-release tablet
  Contraindications   History of seizure disorderHistory of strokeHistory of brain tumor, brain surgery, or serious closed head injuryEating disordersThose taking another form of bupropionMonoamine oxidase inhibitor therapy within previous 14 dAbrupt discontinuation of alcohol or benzodiazepines at same time
  Precautions         PregnancyConcomitant therapy with medications known to lower the seizure threshold
  Dosage              150 mg PO q AM × 3 d, then increase to 150 mg PO BID Treatment should be initiated while patient is still smokingSet quit date 1--2 weeks after initiationDO NOT exceed 300 mg/dAllow at least 8 h between dosesAvoid bedtime dosing to minimize insomniaCan be used safely with NRTIf progression towards abstinence unsuccessful by week 7, discontinueDuration: 8--12 wk, maintenance up to 6 months
  Side effects        Insomnia most common (35%--40%)Dry mouthNervousnessAgitationAnxietyWeight lossConstipationSeizures (risk is 1/1000)
  Advantages          Bupropion can be safely used with NRTBupropion may be beneficial in patients with depressionNo tapering required
  Disadvantages       Seizure risk is increasedMay increase the risk of suicidal thinking in patients who have depression
  ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Transdermal Preparations^OTC/Rx^

  ---------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------
  Products                                                                                   Nicotrol Patch^®^ (McNeil Consumer Healthcare, Fort Washington, PA) 5 mg10 mg, 15 mg (16 hours)                                                  Nicoderm^®^ CQ (Sanofi-Aventis S.A., Paris, France); Generic nicotine patch 7 mg14 mg, 21 mg (24 hours)
  Dosage                                               \>10 cigarettes/day                   15 mg/day × 6 week10 mg/day × 2 week5 mg/day × 2 week                                                                                            21 mg/day × 6 week14 mg/day × 2 week7 mg/day × 2 weeks
  ≤10 cigarettes/day                                   10 mg/day × 6 week5 mg/day × 2 week   14 mg/day × 6 week7 mg/day × 2 weekIf \<100 lbs or cardiovascular disease:14 mg/day × 4--6 week7 mg/day × 2--4 week                              
  Comments[a](#tfn4-cpaa-2-017){ref-type="table-fn"}                                         Remove before bedtimeNicotine released over 16 h                                                                                                 May wear patch for 24 hRemove at bedtime if patient experiences sleep disturbances.
  Contraindications                                                                          PregnancyRecent (2 or less week post-myocardial infarction)Unstable angina pectorisSerious underlying arrhythmias                                
  Side effects                                                                               Local skin reactions: erythema, pruritis, burningHeadacheSleep disturbances: insomnia, vivid dreams                                              
  Advantages                                                                                 Provides consistent nicotine levels over 16--24 hoursEasy to use and concealFewer adherence issuesAvailable without prescription                 
  Disadvantages                                                                              Patients cannot titrate the doseAllergic reactions to adhesivePatients with certain skin conditions cannot use patchPatch may contain aluminum   
  ---------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------

**Notes:** Patch should be applied in the morning when patient wakes on the quit day. Apply on relatively hairless areas between the neck and waist.

###### 

Gum^OTC^

  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product             Nicorette^®^ (GlaxoSmithKline plc, Brentford, London, England, UK), Nicorette DS^®^ (GlaxoSmith-Kline plc, Brentford, London, England, UK), Generic 2 mg, 4 mg; regular, mint, orange

  Contraindications   PregnancyRecent (≤2 weeks) myocardial infarctionSerious underlying arrhythmiasSerious or worsening angina pectorisTemporomandibular joint disease

  Dosage              ≥25 cigarettes/day: 4 mg\
                      \<25 cigarettes/day: 2 mg\
                      Week 1--6: 1 piece q 1--2 hours\
                      Week 2--4: 1 piece q 2--4 hours\
                      Week 10--12: 1 piece q 4--8 hours Chew each piece slowly until peppery or flavored taste emergesPark between cheek and gum when tinglingsensation appearsResume chewing when tingle fadesRepeat chew/park steps until most of the nicotine is gone (taste or tingle does not return; generally 30 minutes)Park in different areas of mouthNo food or beverages 15 minutes before or during use (acidic beverages reduce buccal absorption)If there are strong or frequent cravings, may use a 2nd piece within the hourMax: 24 pieces/day\
                      Duration: Up to 12 week

  Side effects        Mouth sorenessThroat irritationJaw painHiccupsDyspepsiaHypersalivationFlatulenceNausea and vomitingUnpleasant tasteLightheadedness

  Advantages          Might satisfy oral cravingsMay delay weight gainPatients can titrate therapy to manage withdrawal symptomsAvailable over the counter

  Disadvantages       Gum chewing may not be socially acceptableDifficult to use with denturesMay cause loosening of dental fillingsPatients must use proper chewing technique to minimize adverse effects
  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Lozenge^OTC^

  ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product             Commit^®^ (GlaxoSmithKline plc, Brentford, London, England, UK) 2 mg, 4 mg

  Contraindications   PregnancyRecent (≤2 weeks) myocardial infarctionSerious underlying arrhythmiasSerious or worsening angina pectoris

  Dosage              1st cigarette ≤30 min after waking up: 4 mg\
                      1st cigarette \>30 min after waking up: 2 mg\
                      Week 1--6: 1 lozenge q 1--2 hours; minimum 9 per day\
                      Week 7--9: 1 lozenge q 2--4 hours\
                      Week 10--12: 1 lozenge q 4--8 hours Allow lozenge to dissolve slowly (20--30 minutes )Nicotine release may cause a warm or tingling sensationDo not chew or swallow the lozengeRotate the lozenge to different areas of the mouthNo food or beverages 15 minutes before, during or after useDo not use more than 1 lozenge at a timeMax: 5 lozenges every 6 h; 20 lozenges/day\
                      Duration: up to 12 week

  Adverse events      NauseaHiccupsCoughHeartburnHeadache

  Advantages          Might satisfy oral cravingsMay delay weight gainPatients can titrate therapy to manage withdrawal symptomsProvides \~25% more nicotine than gumAvailable over the counter

  Disadvantages       Gastrointestinal side effects might be bothersomeContains phenylalanine
  ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Nasal spray^Rx^

  ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product             Nicotrol NS^®^ (Pfizer, Inc., New York City, NY) Metered spray (0.5 mg nicotine/actuation) aqueous nicotine

  Contraindications   PregnancyRecent (≤2 weeks) myocardial infarctionSerious underlying arrhythmiasSerious or worsening angina pectoris

  Dosage              1--2 doses/h (8--40 doses/day)\
                      One dose: 2 sprays (one in each nostril); each spray delivers 0.5 mg of nicotine to the nasal mucosa Patients should not sniff, swallow, or inhale through the nose as the spray is administeredFor best results, initially use at least 8 doses/dayDO NOT exceed 5 doses/hours and 40 doses/dayGradually decrease usageDuration (maximal): 3 month

  Side effects        Nasal and throat irritation (hot, peppery, or burning sensation)Transient change in sense of smell and tasteRhinitisTearingSneezingCoughHeadacheNausea

  Advantages          Patients can easily titrate therapy to rapidly manage withdrawal symptomsFastest acting nicotine product

  Disadvantages       Nasal/throat irritation may be bothersomeDependence can resultPatients must wait 5 minutes before driving or operating heavy machineryPatients with chronic nasal disorders (allergy, rhinitis, nasal polyps, or sinusitis) or severe reactive airway disease should NOT use the sprayNo optimal tapering schedulePrescription only
  ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Oral inhaler^Rx^

  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product             Nicotrol Inhaler^®^ (Pfizer, Inc., New York City, NY) 10 mg cartridge delivers 4 mg inhaled nicotine vapor
  Contraindications   PregnancyRecent (≤2 weeks) myocardial infarctionSerious underlying arrhythmiasSerious or worsening angina pectoris
  Dosage              6--16 cartridges/d; individualize dosing Initially, use at least 6 cartridges/d for first 3--6 weekBest effects with continuous puffing for 20 minutesNicotine in cartridge is depleted after 20 minutes of active puffing (oral inhalation)Patients should inhale deeply into back of throat or puff in short breathsOpen cartridge retains potency for 24 hoursEach cartridge delivers 4 mg of nicotine over 80 inhalationsAvoid eating or drinking for 15 minutes before and after use (acidic beverages reduce absorption)Duration: Treat for 3 month and then taper over next 3 month
  Adverse events      Mouth and throat irritation (40%)Unpleasant tasteCough (32%)Rhinitis (23%)DyspepsiaHeadache
  Advantages          Patients can easily titrate therapy to rapidly manage withdrawal symptomsThe inhaler mimics hand-to-mouth ritual of smoking
  Disadvantages       Initial throat or mouth irritation can be bothersomeDependence can occurCold temperatures (\<60°F) reduce amount of nicotine deliveredAvoid hot environments (\>77°F) and protect from lightPatients with underlying bronchospastic disease must use with cautionNo definitive tapering schedulePrescription only
  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
